H.C. Wainwright assumed coverage of Phio Pharmaceuticals (PHIO) with a Buy rating and $14 price target Phio’s lead asset is PH-762 is an siRNA-based therapy formulated to safely inhibit PD-1 expression on T cells within the tumor microenvironment to drive anti-tumor activity, the analyst tells investors in a research note. The firm believes the company is “flying under the radar with investors” and has a bullish outlook for the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHIO:
- Phio Pharmaceuticals Reports Positive Phase 1b Trial Results
- 3 Penny Stocks to Watch Now, 4/10/25